Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Many AI startups multiply monthly consumption by 12 and label it Annual Recurring Revenue (ARR). True ARR is contracted and committed. This uncommitted "run rate" revenue is not durable and can disappear overnight if a competitor releases a better product, creating a misleading head fake for stakeholders.

Related Insights

Investors must look beyond headline ARR figures from YC companies. High-growth numbers are often calculated by annualizing a single month's revenue, which can be misleadingly inflated by non-recurring, one-time hardware sales rather than sticky, subscription-based software revenue.

Describing GovTech revenue as 'annually recurring' is misleading because government contracts are often legally prohibited from extending beyond a political administration's term. This makes traditional SaaS valuation models based on ARR fundamentally flawed for the GovTech space, forcing a different approach for founders and investors.

AI companies are selling large, seat-based contracts based on hype and experimental budgets, inflating current ARR. Investors are skeptical because, like early SaaS, customers will eventually demand usage-based or outcome-based pricing, challenging the long-term revenue stability of these startups.

Lin warns that much of today's AI revenue is 'experimental,' where customers test solutions without long-term commitment. He calls annualizing this pilot revenue 'a joke.' He advises founders to prioritize slower, high-quality, high-retention revenue over fast, low-quality growth that will eventually churn.

The ARR/SaaS model, built on predictable human usage, is failing. AI agents can consume resources worth thousands of dollars for a low subscription fee, breaking the unit economics. This forces a shift to metered, consumption-based pricing similar to utilities like electricity.

The practice of multiplying recent, explosive monthly revenue by 12 to create an "annualized" figure is misleading. It assumes a linear growth curve during a "gold rush" period, similar to how companies were overvalued during the pandemic based on temporary trends, and ignores the sheer volatility of the current market.

Beyond outright fraud, startups often misrepresent financial health in subtle ways. Common examples include classifying trial revenue as ARR or recognizing contracts that have "out for convenience" clauses. These gray-area distinctions can drastically inflate a company's perceived stability and mislead investors.

The AI ecosystem has a systemic revenue recognition problem. A single compute token's value can be recognized as ARR multiple times as it's resold down the value chain (e.g., from OpenAI to an application wrapper). This creates inflated, non-durable revenue figures across the industry.

Unlike previous tech cycles where early revenue was a strong signal, the current AI hype creates significant "experimental demand." Companies will try, pay for, and even renew products that don't fully work. Investors must look beyond revenue to assess true product-market fit.

A deceptive practice is emerging where enterprise AI companies report "Contracted ARR" (CARR) as their main revenue metric. They count multi-year deals at full value, even with steep upfront discounts and early customer opt-outs, making reported revenue 3-5x higher than actual live revenue.

AI Companies Mislead Candidates and Investors by Calling Monthly Consumption "ARR" | RiffOn